Ambrosia's sweet $100m round, and other biofinancings
Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Immunovant's thyroid eye disease drug flunks pivotal trials
Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
AZ claims another win for Imfinzi in frontline liver cancer
AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Threat of Trump's pharma tariffs looms again
The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
Alzheimer's biotech Korsana to go public via reverse merger
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey
The Industry’s Most Comprehensive End-to-End TCE Forum
The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.